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Abstract The exonization of an Alu-like element into a coding
sequence is unique to primates and this phenomenon distin-
guishes our genome from other mammals. Here, we report the
presence of a special splicing variant of a proapoptotic protein
Bcl-rambo in human lymph node, designated as Bcl-rambo beta.
This variant contains a 98 bp Alu-like sequence which acts as an
exon. There exists an in-frame stop codon within this inserted
Alu-like cassette, resulting in generation of a premature protein
of 104 amino acid residues. Unlike the Bcl-rambo, Bcl-rambo
beta is lacking of the BH1, BH2 and BH3 motifs and becomes a
BH4-only protein. Bcl-rambo beta is detected in several adult
human tissues such as heart, lymph node and cervix but is
absent in human brain tissue. In addition, Bcl-rambo beta is
found not to be associated with mitochondria due to the absence
of its C-terminal membrane anchor region. Nevertheless, this
cytosol-localized protein is capable of promoting etoposide-
and Taxol-induced cell death. Although the exact function of
the Alu sequence is not fully characterized, the Alu element
within the Bcl-rambo beta appeared to contribute to the pro-
apoptotic capability, since removing of the Alu sequence from
Bcl-rambo beta abrogates its ability to induce cell death. Our
data support the speculation that the Alu element insertion dur-
ing the splicing process may play an important role in the gen-
eration of protein diversity in primate cells by a yet uncharac-
terized mechanism.
- 2002 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
Apoptosis, also known as programmed cell death (PCD), is
a genetically regulated cellular suicide mechanism that plays a
vital role in development and in the defense of homeostasis
[1]. One of the major components of cell apoptosis machinery
is the Bcl-2 family. Up to now, more than 20 members of this
family have been characterized in mammals [2,3]. The Bcl-2
family includes both anti-apoptotic and proapoptotic proteins
containing one or more Bcl-2 homology (BH) domains. The
anti-apoptotic subfamily includes e.g. Bcl-2 and Bcl-XL and
the proapoptotic subfamily consists of e.g. Bax, Bid and Bak.
In addition, the proapoptotic Bcl-2 subfamily can be further
divided into two groups. One includes proteins that contain
three Bcl-2 homology domains (BH1^3) such as Bax and Bak,
while the other group involves proteins that contain the BH3
domain only, which can be represented by Bad and PUMA
[2,3].
Recently Kataoka et al. have identi¢ed a novel Bcl-2 ho-
molog Bcl-rambo which shows high homology to the proteins
of the Bcl-2 family containing BH domains 1^4. However,
unlike Bcl-2, Bcl-rambo possesses a unique 250 amino acid
long C-terminal extension. Bcl-rambo is localized to mito-
chondria and possesses proapoptotic capability that can be
speci¢cally blocked by the caspase inhibitors IAPs. Interest-
ingly, the induction of cell death by Bcl-rambo is dependent
on its unique C-terminal extension rather than its BH motifs.
Thus, Bcl-rambo forms a new type of proapoptotic Bcl-2
member that promotes cell death independently of its BH
motifs [4].
In the course of studying the function of the Bcl-rambo, we
cloned a splicing variant Bcl-rambo beta from the human
lymph node cDNA library. Surprisingly, this variant contains
a 98 bp Alu-like insertion as an exon and there is an in-frame
stop codon within this inserted sequence, resulting in expres-
sion of a 104 amino acid protein, which contains only a BH4
domain. We report here the gene structure of Bcl-rambo beta
and propose its splicing mechanism for exonization of the Alu
sequence. By expressing GFP-Bcl-rambo beta fusions in living
cells, we were able to demonstrate that Bcl-rambo beta has a
di¡used localization throughout the cells. It is interesting to
note that lacking of the C-terminal extension of Bcl-rambo
beta does not compromise its function in promoting apoptosis
induced by etoposide and Taxol as expected. Deletion of the
Alu sequence from the Bcl-rambo beta abolished its proapop-
totic activity, indicating that the Alu sequence may be in-
volved in the proapoptotic function of Bcl-rambo beta.
2. Materials and methods
2.1. Reagents and antibodies
The following antibodies were used in this study: monoclonal anti-
body mAb-GFP was purchased from MBL (Japan) and monoclonal
antibody mAb-Flag was from Sigma. Etoposide and Taxol used in
this study were of GCP grade. Restriction enzymes were purchased
from New England Biolabs (USA) and Takara (Japan). Medium
compounds for culturing of Escherichia coli were ordered from Oxoid
(UK). Majority of biochemical reagents were purchased from Sigma.
Mitotracker Red CMXRos was ordered from Molecular Probes
(USA).
2.2. Oligonucleotides
The sequences of the oligonucleotides used in this study are as
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follows (all primers are read from 5P to 3P) : P1: CCGGAATTCATG-
GCGTCCTCTTCTACTGT; P2: CTGTAATCCTGGCTACTCAG-
G; P3: CCGTCGACCTATTTCTTTCTCAGAGCCA; P4: CGGTC-
GACCTAAGACTTGCCCTCAGACAGCGG (the reverse primer for
Bcl-rambo-vMA); P5: CGCTCGAGCTATTCAGAAATTTCTTTG-
TC (the reverse primer for Bcl-rambo-BH4).
2.3. Polymerase chain reaction (PCR) conditions
One microgram of primer was added to a 20 ul reaction volume
containing 2 mM MgCl2, 250 uM of each of deoxynucleotides, and 25
U of Taq polymerase. The mixture was incubated ¢rst at 94‡C for 10
min, followed by 30 cycles of 94‡C denaturing for 1 min, 54‡C anneal-
ing for 1 min, and 72‡C for 3 min. After 30 cycles, another 10 min
were added to ensure the completion of all the extension at 72‡C.
2.4. Plasmid construction
The full-length gene fragments of Bcl-rambo (1458 bp) and Bcl-
rambo beta (1342 bp) were both cloned into the EcoRI/XhoI sites
of plasmid pcDNA3-FLAG (gift from Dr. Sun, Stanford University)
and the EcoRI/SalI sites of plasmid pEGFP-C1 (gift from Dr. Yao,
UC Berkeley) respectively to generate four recombinant expres-
sion vectors pcDNA3-FLAG-Bcl-rambo, pcDNA3-FLAG-Bcl-rambo
beta, pEGFP-C1-Bcl-rambo and pEGFP-C1-Bcl-rambo beta. The
fragments of Bcl-rambo-vMA (membrane anchor, 1377 bp) and
Bcl-rambo-BH4 (231 bp) were cloned into the EcoRI/SalI sites to
generate recombinant plasmids pEGFP-C1-Bcl-rambo-vMA and
pEGFP-C1-Bcl-rambo-BH4, respectively. All cloned gene fragments
were veri¢ed by DNA sequencing using ABI Prism automated se-
quencing method.
2.5. Cell culture and transfection
The 293A cells were purchased from QBI (USA). The human cer-
vical HeLa cancer cell line was kindly provided by Dr. Yao (UC
Berkeley, USA). Cells were maintained in Dulbecco’s minimal Eagle’s
medium (DMEM) containing 10% heat-inactivated bovine serum,
1 mM glutamine, 100 units/ml penicillin, 100 ug/ml streptomycin
(Life Technologies, Inc., Grand Island, NY, USA) at 37‡C under
an atmosphere of 5% CO2 in air. Transfection of cultured cells with
various mammalian expression vectors by lipofectamine (Life Tech-
nologies, Inc.) was according to the methods provided by the manu-
facturer’s speci¢cation.
2.6. Cell viability assay
The 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide
(MTT) assay was used to determine cell viability. Brie£y, cells were
plated at 1U104 cells/well in 96-well microtiter plates overnight and
then transfected with indicated plasmids by lipofectamine. Cells were
then treated with 100 ul fresh medium containing 60 ug of etoposide,
cultured for 5 h followed by an additional 3 h incubation with 250 ug/
ml MTT solution. After incubation, the medium was removed and
replaced with 100 ul dimethyl sulfoxide (DMSO) and the data were
analyzed using a microplate reader at a wavelength of 570 nm. The
formula used to translate the cell viability to the percentage of cell
death is : %x = (Vx3Vempty)/VemptyU100% (%, percentage of cell
death; x, transfected gene of interest; V, the cell viability value;
empty, vector alone.)
2.7. Manipulation of nucleic acids and miscellaneous methods
Standard methods are used for the transformation of E. coli, prep-
aration of recombinant plasmids from E. coli, restriction enzyme map-
ping, and isolation and ligation of restriction fragments [5].
3. Result
3.1. Identi¢cation of the Bcl-rambo beta
In the course of investigating the function of Bcl-rambo, we
performed a PCR ampli¢cation using the human lymph node
cDNA library (Clontech, USA) as template. Two oligonucleo-
tides P1 and P3 (see Section 2 and Fig. 4A) were used as
primers. Unexpectedly, two prominent ampli¢ed fragments
with molecular sizes of 1.4 and 1.3 kb were visualized on
1% agarose gel. The longer PCR product (1.4 kb) was con-
¢rmed to be the full-length Bcl-rambo and the shorter form
(1.3 kb) was later identi¢ed as a variant of Bcl-rambo by
DNA sequencing determination. The short form of Bcl-rambo
was then designated as Bcl-rambo beta by us and its complete
nucleotide sequence has been deposited in GenBank with an
assigned accession number of AF539453. Di¡erent from Bcl-
rambo, Bcl-rambo beta has an additional 98 bp insertion after
exon 2, but skips two exons corresponding to exons 4 and 5 of
the Bcl-rambo (Fig. 1A). The amino acid sequences of Bcl-
rambo and Bcl-rambo beta were aligned in Fig. 1B. Compar-
ison of the two protein sequences indicated that the Bcl-ram-
bo beta only contains the BH4 domain and its C-terminal
expressed by Alu insertion is completely di¡erent from that
of the Bcl-rambo.
3.2. The 98 bp insertion of Bcl-rambo beta derives from an
Alu element
BLAST homology search of the nucleotide sequence of
the inserted 98 bp in the Bcl-rambo beta with the Gen-
Bank database revealed a remarkable homology (91%) with
human Alu repeat sequences. The nucleotide sequence of
this Alu insertion is shown in Fig. 2A. This sequence was
used to compare with several reported sequences of Alu sub-
families and they displayed high similarities to each other
(Fig. 2B).
The sequence of the Bcl-rambo was mapped to the human
genome (22q11) and at least eight Alu repeat sequences were
identi¢ed in the total of ¢ve introns. Sequence alignment anal-
ysis showed that the 98 bp Alu sequence of Bcl-rambo beta
perfectly matched with an intron sequence segment corre-
sponding to the nucleotides 77554^77653 between exons 2
and 3 of Bcl-rambo (GenBank accession number AC006285,
deposited by Fang, F. et al.), indicating that the Bcl-rambo
beta is generated by a unique alternative splicing mechanism.
There were conserved 5P donor and 3P acceptor sites in these
spliced intron sequences. Based on these conserved splice sites,
we hypothesized a model for the splicing mechanism of Bcl-
rambo beta as depicted in Fig. 3.
3.3. The tissue distribution of Bcl-rambo beta
There exist three stop codons within the inserted Alu cas-
sette, one of which serves as the terminal signal for the trans-
lation of Bcl-rambo beta (Fig. 2A). The resulting premature
open reading frame (ORF) of Bcl-rambo beta contains only
104 amino acids. To examine whether the Bcl-rambo beta
naturally exists in the tissue and what the distribution pattern
for the Bcl-rambo beta is, we performed PCR reactions using
four di¡erent cDNA libraries made from adult tissues of hu-
man heart, lymph node, brain and cervix (HeLa cells) as tem-
plates. Primers P1 and P2 (sequence-speci¢c primers designed
to base-pair with the sequence (nucleotides 307^327) within
the Alu cassette) were used in the PCR ampli¢cation to detect
the ORF of Bcl-rambo beta (320 bp) and primers P1 and P3
were used to amplify the full length of Bcl-rambo (Fig. 4A).
An ampli¢ed band with expected size of approximately 320 bp
of the Bcl-rambo beta was obtained, which is consistent with
the observation that two adjacent bands were ampli¢ed when
P1 and P3 were used as primers. This result indicates that Bcl-
rambo and Bcl-rambo beta coexist in the same tissues. It is
interesting to note that both the Bcl-rambo and the Bcl-rambo
beta were hardly detected in brain tissue indicating that their
transcription and/or splicing may be tissue selective (Fig. 4B).
An extra band of approximately 600 bp was also generated by
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the PCR using human lymphocyte as template (Fig. 4B),
which may represent an unknown isoform of Bcl-rambo.
The exact nature of this PCR product is currently under in-
vestigation.
3.4. The Bcl-rambo beta displays a di¡used localization
throughout the cell
The Bcl-rambo beta lacks the membrane anchor (MA) do-
main in its C-terminal extension due to the premature trans-
lation termination. The MA region is believed to be essential
for the localization of Bcl-rambo in the mitochondria. To
examine the subcellular localization of Bcl-rambo beta,
GFP-Bcl-rambo beta recombinant fusion construct was
made and transfected into HeLa cells. The location of the
GFP-Bcl-rambo beta was imaged by £uorescent microscopy
and the result is shown in Fig. 5B. GFP-Bcl-rambo beta dis-
played an evenly di¡used localization throughout the trans-
fected HeLa cells when compared with Mitotracker Red stain-
ing control (Fig. 5B, c and cP). To further compare its
subcellular localization patterns with GFP-Bcl-rambo and
GFP-Bcl-rambo-vMA, two GFP fusion plasmids pEGFP-
C1-Bcl-rambo and pEGFP-C1-Bcl-rambo-vMA were trans-
fected into the HeLa cells and the £uorescence images are
shown in Fig. 5B, b and d. As expected, the GFP-Bcl-rambo
was localized in the mitochondria (Fig. 5B, b), when com-
pared with its corresponding locations stained with the mito-
chondrial dye Mitotracker Red (Fig. 5B, bP). The location of
expressed GFP-Bcl-rambo-vMA in HeLa cells was found to
be mainly in the cytosol. This result is somehow di¡erent from
what Kataoka et al. reported previously [4], they claimed Bcl-
rambo lacking the MA region exhibited a di¡used nuclear
localization. At present, this apparent discrepancy cannot be
 
Fig. 1. The structural comparison between Bcl-rambo and Bcl-rambo beta. A: The schematic diagram of intron/exon structure of Bcl-rambo
and Bcl-rambo beta. Exons numbered I^VI are represented as open boxes. The Alu-like sequence is represented as black box. The shaded parts
within the boxes I and VI represent the 5P and the 3P untranslated regions, respectively. The initiate start ATG and the termination TGA are
also denoted by arrows. B: Alignment of the protein sequence of Bcl-rambo beta to the ¢rst 104 amino acids of Bcl-rambo. The identical ami-
no acids are shaded and the BH4 domain is boxed.
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explained clearly, however the possibility of utilization of dif-
ferent host cell types for transfection resulting in a di¡erent
subcellular localization pattern can not be dismissed. To clar-
ify whether the Alu sequence per se contributes to the di¡used
localization of Bcl-rambo beta, the Alu sequence (98 bp) was
deleted from the Bcl-rambo beta gene and the resulting frag-
ment containing BH4 domain was cloned into pEGFP-C1
to generate the recombinant plasmid pEGFP-C1-Bcl-rambo-
BH4 (shown in Fig. 5A). After transfection the localization of
GFP-Bcl-rambo-BH4 was shown in Fig. 5B, e and eP. The
Bcl-rambo beta without the Alu sequence at the C-terminal
exhibited a similar subcellular localization pattern as that of
Bcl-rambo beta (Fig. 5B, c and cP), indicating the Alu se-
quence alone probably has no e¡ect on the subcellular distri-
bution. Western blotting analysis was also performed to verify
the expression of all transfected genes in the HeLa cells and
the results are shown in Fig. 5C.
 
 
 
Fig. 2. DNA sequence alignment of the Alu sequence in Bcl-rambo beta with ¢ve Alu subfamilies. A: The nucleotide sequence of the Alu in-
sert in Bcl-rambo beta. Three potential stop codons are boxed. The TGA in shaded box is the real stop codon for Bcl-rambo beta. B: Se-
quence alignment of the 98 bp Alu sequence of Bcl-rambo beta with ¢ve reported Alu repeat sequences. The identical nucleotides are shaded.
AluSg, AluSq, AluSx, AluY, AluYb (U82670) are ¢ve di¡erent subfamilies of the Alu repeat element. The sequences were aligned by DNAstar
MegAlign program.
Fig. 3. The proposed splicing mechanism for Bcl-rambo beta. Bcl-
rambo beta is generated by splicing of Bcl-rambo at the junctions
between exons 2 and 3. Conserved 5P donor site (GT) and 3P accep-
tor site (AG) that can be recognized by spliceosome are underlined.
Exons are represented as boxes.
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3.5. The Bcl-rambo beta promotes etoposide- and
Taxol-induced cell death
Bcl-rambo contains a unique C-terminal extension that is
reported to be essential for its proapoptotic capability [4].
Since Bcl-rambo beta lacks this C-terminal extension, we
then examined whether Bcl-rambo beta still functions in cell
apoptosis. HeLa cells and 293A cells were transfected with
pcDNA3-Flag empty vector, pcDNA3-Flag-Bcl-rambo and
pcDNA3-Flag-Bcl-rambo beta respectively and were then
treated with Taxol (100 nM) or etoposide (8 ug/ml) as apo-
ptotic stimuli. Results from the MTT cell death assay were
shown in Fig. 6A. To our surprise, the Bcl-rambo beta was
found to promote Taxol- or etoposide-induced cell death even
more strongly than Bcl-rambo (Fig. 6A, a and b). In addition,
the proapoptotic e¡ect triggered by the Bcl-rambo beta can be
partially blocked by Bcl-XL, suggesting that the Bcl-rambo
beta-induced apoptosis is dependent on the mitochondrial
pathway (Fig. 6A, b).
HeLa cells were transfected with pEGFP-C1 control vec-
tor, pEGFP-C1-Bcl-rambo, pEGFP-C1-Bcl-rambo beta and
pEGFP-C1-Bcl-rambo-BH4. 36 h after the transfection the
cells were observed under £uorescent microscopy. A majority
of the cells transfected with pEGFP-C1-Bcl-rambo beta be-
came rounded and detached from the culture dish (Fig. 6B, c),
whereas cells transfected with the other three plasmids, espe-
cially the pEGFP-C1-Bcl-rambo-BH4, remained morphologi-
cally unchanged (Fig. 6B, a, b and d). Consistent with this
observation, GFP-Bcl-rambo beta protein was barely detected
in the Western blotting experiment (Fig. 5C). These results
indicate that overexpression of the Bcl-rambo beta induced
the cell death in HeLa cells and the Alu sequence per se
may contribute to the proapoptotic ability of Bcl-rambo beta.
4. Discussion
The insertion by an Alu-like element in mature mRNA is
not unusual [6,7]. Sorek et al. [8] and Hide et al. [9] have
analyzed about 150 genes that all contain Alu insertion by
aligning a database of ESTs and cDNAs to the human ge-
nome. They have concluded that all the Alu exons are alter-
natively spliced. In addition, it has been reported recently that
transposable elements are found in protein-coding regions of
about 4% human genes, and Alu elements account for one-
third of these insertions [10]. Some of these insertions are
correlated with genetic diseases. For example, Ferlini et al.
have identi¢ed a genomic sequence with features characteristic
of Alu-like mobile elements rearranged into the dystrophin
gene in a family a¡ected by X-linked dilated cardiomyopathy
[11]. Mitchell and coworkers have also found that there exists
a 142 bp Alu sequence insertion in mature mRNA that asso-
ciates with the de¢ciency of ornithine delta-aminotransferase
[12]. At present, it is not clear whether an Alu sequence in-
sertion into Bcl-rambo is connected to some speci¢c diseases.
Bcl-rambo beta is not the only example for the inclusion of an
Alu sequence into Bcl-2 family genes. For example, by com-
putational blast search, we have found for the ¢rst time that
Bim-beta3, a variant of Bcl-2 family protein, also contains an
Alu sequence at the C-terminal similar to Bcl-rambo beta [15].
The ¢nding that exonization of the Alu sequence occurs in
two Bcl-2 family members may be explained by that there
exists a unique device in primate cells to increase the variabil-
ity and versatility of Bcl-2 family proteins.
Based on the statistic data obtained by Sorek et al., the
insertion of an Alu sequence on the mRNA is random.
Over 80% of Alu sequences are inserted in the coding region,
whereas less than 20% are inserted either in the 5P or 3P un-
translated region. In the case of Bcl-rambo beta, the Alu
cassette is inserted into the coding region of Bcl-rambo. The-
oretically, there will be three e¡ects caused by Alu sequence
insertion into the protein-coding region, namely, to add a new
domain, to create an alternative translational start codon and
to cause a premature termination [8]. As shown in Fig. 2A,
there exist three stop codons in all three possible reading
frames within the Alu sequence inserted in the Bcl-rambo,
therefore, translation from the ATG start of Bcl-rambo will
be terminated anyway at one of these three stop codons, giv-
ing rise to a premature form of Bcl-rambo beta.
Another unusual phenomenon of Bcl-rambo beta splicing is
that the inclusion of the Alu exon leads to the skipping of two
downstream consecutive exons. A similar example was found
that insertion of an Alu repeat also causes the skipping of the
following exon in human beta-glucuronidase gene, which was
reported to be associated with MPS VII in some patients [16].
The exact molecular mechanism underlying this exon skipping
is not fully understood.
The Bcl-rambo beta is distinctive from the Bcl-rambo and
 
 
 
Fig. 4. Tissue distribution of Bcl-rambo beta. A: The primers P1,
P2 and P3 are indicated at their proper positions. P1 and P2 were
used to amplify the coding region of Bcl-rambo beta. P1 and P3
can amplify both Bcl-rambo and Bcl-rambo beta when using human
tissue cDNA libraries as template. P2 was speci¢cally designed to
complement the 3P end of the inserted Alu sequence from nucleo-
tides 307^327. B: Results from PCR ampli¢cation using four adult
human tissue cDNA libraries as template (human brain, human
heart, human lymph node and HeLa cells). The upper panel shows
the PCR result using P1 and P3 as primers and the middle panel is
the PCR result using P1 and P2 as primers. In the lower panel,
beta-actin was used as an internal control to ensure equal amount
of the template used.
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some other Bcl-2 family members in several aspects. First of
all, unlike Bcl-rambo, which is present in the mitochondria,
Bcl-rambo beta is found in the cytosol due to the lack of the
MA region [4]. Secondly, di¡erent from Bad or Bax, the ab-
sence of the MA region in Bcl-rambo beta eliminates the
possibility of translocation of this variant from cytosol to
the mitochondria when the cells are undergoing apoptosis
[13]. Last but not least, although Bcl-rambo beta does not
contain the BH3 domain, which is required for some Bcl-2
family members such as Bax or Bid in inducing apoptosis [2],
still it retains proapoptotic capability. Nevertheless, Bcl-ram-
bo beta is not the sole example to possess that property. As an
analogy, BNIP3, a member of the Bcl-2 family, when deleting
both BH3 domain and membrane anchor (MA), was shown
 
 
 
 
 
 
          
    
    
 
 
 
 
 
 
 
 
  
  
    
Fig. 6. Bcl-rambo beta potentiates etoposide- and Taxol-induced cell death. A: 293A cells (a) and HeLa cells (b) were plated separately onto a
96-well plate and were transfected with pcDNA, pcDNA-Bcl-rambo and pcDNA-Bcl-rambo beta and the viability of the cells was determined
by the MTT method. The 100% viable cells were de¢ned by measurement obtained from the untransfected cells. Values shown are meansUS.D.
of triplicate samples. B: HeLa cells were transfected with control vector pEGFP-C1 (a), pEGFP-C1-Bcl-rambo (b), pEGFP-C1-Bcl-rambo beta
(c) and pEGFP-Bcl-rambo-BH4 (d). Most of the Bcl-rambo beta transfected cells become rounded and detached from the plate at 36 h after
transfection (c).
6
Fig. 5. Subcellular localization of Bcl-rambo beta, Bcl-rambo, Bcl-rambo-vMA and Bcl-rambo-BH4. A: The diagram of four recombinant plas-
mids, GFP inserted. The conserved Bcl-2 homology motifs (BH3 and BH4) are shaded in gray; the membrane anchor domain (MA) is shaded
in light gray; the Alu sequence is slashed and GFP is shaded in black. B: HeLa cells were transfected with pEGFP-C1 control vector (a and
aP), pEGFP-C1-Bcl-rambo (b and bP), pEGFP-C1-Bcl-rambo beta (c and cP), pEGFP-C1-Bcl-rambo-vMA (d and dP) and pEGFP-C1-Bcl-
rambo-BH4 (e and eP). 15 h after transfection cells were stained with Mitotracker Red (100 nM) for 30 min. The subcellular localization of
each GFP fusion protein was determined by £uorescent microscopy. Cells positive for both GFP and Mitotracker Red are indicated by arrows.
C: Western blotting analysis was performed using the anti-GFP monoclonal antibody (MBL, Japan) to verify the expression of all transfected
genes in the HeLa cells.
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to be una¡ected in its proapoptotic capability [14], indicating
the mechanisms by which Bcl-2 family proteins function in
apoptosis may be £exible.
To our knowledge, the Bcl-rambo beta is the ¢rst gene
identi¢ed containing an Alu sequence insertion which may
be correlated with the proapoptotic activity. The detail mech-
anism of how the Bcl-rambo beta and its Alu sequence are
involved in the apoptosis awaits further investigation.
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